S. Celik Et Al. , "Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer," Journal of B.U.ON. , vol.26, no.6, pp.2577-2584, 2021
Celik, S. Et Al. 2021. Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer. Journal of B.U.ON. , vol.26, no.6 , 2577-2584.
Celik, S., Erol, A., Gokbayrak, O., SARI, H., Yilmaz, B., MUNGAN, M. U., ... YÖRÜKOĞLU, K.(2021). Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer. Journal of B.U.ON. , vol.26, no.6, 2577-2584.
Celik, Serdar Et Al. "Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer," Journal of B.U.ON. , vol.26, no.6, 2577-2584, 2021
Celik, Serdar Et Al. "Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer." Journal of B.U.ON. , vol.26, no.6, pp.2577-2584, 2021
Celik, S. Et Al. (2021) . "Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer." Journal of B.U.ON. , vol.26, no.6, pp.2577-2584.
@article{article, author={Serdar Celik Et Al. }, title={Assessment of ex-vivo efficacy of immunotherapeutic agents in intermediate-risk and high-risk non-muscle invasive bladder cancer}, journal={Journal of B.U.ON.}, year=2021, pages={2577-2584} }